Insights & news

Belgium – Cannabis for Medical Use – Update

  • 19/09/2019
  • News

As a follow-up to the Van Bael & Bellis Life Sciences Newsflash of 12 March 2019, please find below the latest on medical cannabis in Belgium. 

 

  • Following the publication on 20 May 2019 of the Law of 7 April 2019 amending the provisions on the provision of scientific and technical advice by the Federal Agency for Medicines and Health Products and on the financing of the Federal Agency for Medicines and Health Products as well as the establishment of a cannabis office’’, which provides the statutory basis for a Cannabis Office and the controlled cultivation and commercialization of cannabis in Belgium, we are still waiting for the publication of detailed implementing rules in the form of (a) Royal Decree(s). This may still take some time as there is yet a coalition to be formed for a new federal government following the national elections of 26 May 2019. The current caretaker government does not have the powers to adopt the requisite Royal Decree(s).
     
  • Once operational, the Cannabis Office will oversee and control cannabis activities in Belgium. The Cannabis Office will issue a call for tenders for the cultivation of a certain limited amount of cannabis. Licences will be granted to the successful applicants to cultivate cannabis in specified locations. The Cannabis Office will purchase the harvest and export and/or distribute it.
     
  • Since 2015, Belgian pharmacists were allowed to dispense “prepackaged” cannabis-based authorised medicines (e.g., Sativex®) and magisterial preparations on the basis of cannabidiol (“CBD”) powder. However, the pharmacists were prohibited from dispensing magisterial or officinal preparations for human or veterinary use which contain one or more tetrahydrocannabinols (“THC”) (Royal Decree of 11 June 2015). THC is the main psychoactive compound of cannabis. In practice, this meant that no magisterial preparations were dispensed as all CBD can contain trace amounts of THC. Patients therefore travelled abroad to obtain such preparations. However, on 16 July 2019, the Federal Agency for Medicines and Health Products (the “FAMHP”) issued a circular No. 648 (See, attached Dutch and French versions) in which it “interprets” the Royal Decree of 11 June 2015. The FAMHP states that the Royal Decree of 11 June 2015 was not intended to prohibit pharmacists from using CBD powder with trace amounts of THC and lays down criteria to determine whether a pharmacist is allowed to use a raw material contaminated with THC in a magisterial preparation. More particularly, raw material with trace amounts of THC can be used for magisterial preparations if the patient is exposed to maximum 1 microgram Δ9-THC per kilogram of body weight per day. The highest daily dose being 1,500 mg for a person weighing 75 kg, it cannot contain more than 75 micrograms Δ9-THC. This corresponds with a contamination of 0.0005%.
     
  • Based on the publicly available information, we understand that, following the adoption of circular No. 648, the FAMHP has already authorised one company (Fagron) to supply CBD powder to pharmacists for use in magisterial preparations.
     
  • On 11 September 2019, members of the Christian Democratic party CD&V submitted to the Chamber of Representatives a draft resolutionin favour of the therapeutic use, under strict conditions, of cannabinoids in order to soothe pain in case of specific spasmodic symptoms”. While it is uncertain whether the draft resolution will eventually manage to secure a parliamentary majority, it calls on the federal government to:

o   invest in further clinical research on the efficacy of cannabinoids to control pain and spasmodic symptoms;

o   extend, based on the aforementioned research, the indications for which the therapeutic use of cannabinoids is authorised for patients on whom other medicinal products have no or little effect, and for whom medical cannabis has clinically proven benefits in view of combating pain and spasmodic symptoms;

o   invest in research on the safe and controlled production of CBD oil, composed of 5% CBD and 2% THC;

o   approve, based on the above research, CBD oil as a medicinal product, composed of 5% CBD and 2% THC, so as to authorise its supply by hospital pharmacies, under the strict medical supervision of a physician, to patients on whom other medicinal products have no or little effect, and for whom medical cannabis has scientifically proven benefits, and this at least to patients suffering from multiple sclerosis, amyotrophic lateral sclerosis or epilepsy;

o   extend the therapeutic use of Sativex® to patients suffering from amyotrophic lateral sclerosis; and

o   examine the possibility of authorizing imports of approved and safe CBD oil while the production of CBD oil is not yet legalised in Belgium.

 

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 14/10/2021
    • Articles

    European Commission Proposes to Delay Application of Regulation on In Vitro Diagnostic Medical Devices

    The European Commission (the Commission) published today a proposal for a Regulation delaying the application of Regulation (EU) 2017/746 on in vitro diagnostic medical devices (the IVDR) by three to five years, depending on the risk involved in the devices concerned (Proposal for a Regulation of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and deferred application of requirements for in-house devices – the Proposal; see, attached copy). The IVDR was set to take effect on 26 May 2022. Referring to the extraordinary circumstances created by the COVID-19 pandemic and the resulting delay in the designation and work of notified bodies under the IVDR, the Proposal stresses that immediate action is necessary to avert a “significant disruption in the supply of in vitro diagnostic medical devices on the market both for health institutions and for the public” (p. 2). To date, only six notified bodies have been designated under the IVDR. Moreover, these six notified bodies are established in only three countries (France, Germany and the Netherlands). Extending the existing transitional period for devices covered by a valid certificate issued under the current in vitro diagnostic medical devices Directive (Directive 98/79/EC) by one year, the Proposal provides that these devices can continue to be placed on the market or put into service until 26 May 2025. Furthermore, the Proposal introduces tailored transitional periods for devices that have to undergo a conformity assessment involving notified bodies for the first time under the IVDR. For these devices, the length of the transitional period will depend on the risk class of the device concerned. Lower risk devices such as class B and class A sterile devices will benefit from a transition period until 26 May 2027, whereas higher risk devices (class D and class C devices) will only have a transition period until, respectively, 26 May 2025 and 26 May 2026. The Proposal responds to a widespread call for delayed application of the IVDR. This call is not new though. As early as in April 2020, the European trade association for the medical devices sector, MedTech Europe, warned that “even before the COVID-19 pandemic, very little progress had been achieved yet, to get the new IVDR regulatory system ready” and that “since the present COVID-19 outbreak, the IVDR implementation progress has come to a total halt” (see, Van Bael & Bellis Life Sciences News and Insights of 24 April 2020).

    Read more
    • 11/10/2021
    • Articles

    EU Clinical Trials Regulation - EMA Publishes Clinical Trial Information System Go-live Plan

    On 8 October 2021, the European Medicines Agency (EMA) provided an update on the progress in the development and preparations for the ‘go-live’ of the Clinical Trial Information System (CTIS) on 31 January 2022. EMA also published a 12-page CTIS go-live plan summarising the key steps remaining before the launch of CTIS (the Plan; see, attached copy). According to EMA and the Plan, CTIS is currently being extensively tested to identify any potential remaining stability issues. A key priority in preparing CTIS for launch is ensuring that the sponsor workspace is fully functional. Once this has happened, the workspace for health authorities will be finished, followed by the public portal. Other priorities are to set up a dedicated helpdesk for CTIS users and to prepare materials for “extended stakeholder training”. These materials will complement the existing training materials already issued by EMA, including online training modules and a sponsor handbook (see, Van Bael & Bellis Life Sciences News and Insights of 9 August 2021). Further preparations are also necessary to allow for clinical trial safety reporting and monitoring as included in the initial scope of CTIS activities. The Plan provides for all of the outstanding matters a chart with a timeline for their implementation. In the first quarter of 2022, EMA will publish a follow-up plan focusing on the activities post 31 January 2022 which will cover post go-live releases, CTIS operation and maintenance, continued training offerings and stakeholder support and interaction. CTIS is the cornerstone for the application of the EU Clinical Trials Regulation (i.e., Regulation (EU) No 536/2014 of 16 April 2014). Comprising an EU Portal and EU Database, CTIS will ensure a single-entry point for the submission of data and information relating to clinical trials by sponsors, evaluation and supervision by Member State health authorities, and access to publicly available data and information relating to clinical trials by the public (see, Van Bael & Bellis Life Sciences News and Insights of 22 April 2021 and Van Bael & Bellis Life Sciences News and Insights of 9 August 2021).

    Read more
    • 11/10/2021
    • Articles

    Belgium, Ireland, and The Netherlands Jointly Agree under Aegis of Beneluxa Initiative to Reimburse Zolgensma®

    On 8 October 2021, Belgium, Ireland, and The Netherlands announced that they had reached an agreement with Novartis Gene Therapies (Novartis) regarding the reimbursement of Zolgensma® (onasemnogene abeparvovec), a gene therapy medicinal product that was designated as an orphan medicine and is indicated for the treatment of two specific types of Spinal Muscular Atrophy (SMA) (see, attached press release). SMA is the most common genetic cause of mortality in infants and affects nerve cells that cause general muscle weakness. Infants with SMA typically do not survive more than two years. For its part, Zolgensma® is known as the world’s priciest medicine, but the press release does not address the price reductions which Novartis is understood to have consented to in order to secure reimbursement in the three countries. The agreement was reached under the aegis of the Beneluxa initiative, a collaborative effort of Austria, Belgium, Ireland, Luxemburg, and The Netherlands designed to expand patient access to high quality and affordable medicines. Under the Beneluxa initiative member governments pursue joint activities in the areas of (i) horizon scanning; (ii) Health Technology Assessment; (iii) the sharing of information; and (iv) pricing and reimbursement. The arrangement with regard to Zolgensma® is the first agreement governing the price and reimbursement of a medicine involving 3 countries. The previous one only applied to two countries, Belgium and The Netherlands, but, interestingly, related to Biogen’s Spinraza® (nusinersen), a medicine also indicated for the treatment of specific SMA conditions (see, Van Bael & Bellis Life Sciences News & Insights of 12 July 2018). Zolgensma® will qualify for reimbursement in Ireland with immediate effect. In The Netherlands, the medicine will be reimbursable on 1 November 2021, while Belgium will reportedly follow suit on 1 December 2021.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *